WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H572446
CAS#: 1028089-05-5
Description: PEG8-Tos is a PEG derivative containing a hydroxyl group with a tosyl group. The PEG linker contains 7 units of ethylene glycol. The hydrophilic PEG spacer increases solubility in aqueous media. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. The tosyl group is a very good leaving group for nucleophilic substitution reactions.
Hodoodo Cat#: H572446
Name: PEG8-Tos
CAS#: 1028089-05-5
Chemical Formula: C21H36O10S
Exact Mass: 480.20
Molecular Weight: 480.570
Elemental Analysis: C, 52.49; H, 7.55; O, 33.29; S, 6.67
Synonym: PEG8-Tos; PEG8-Tosylate; Tos-PEG8-OH; Tos-PEG8;
IUPAC/Chemical Name: 20-hydroxy-3,6,9,12,15,18-hexaoxaicosyl 4-methylbenzenesulfonate
InChi Key: OPGOVMSKPDWRRQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H36O10S/c1-20-2-4-21(5-3-20)32(23,24)31-19-18-30-17-16-29-15-14-28-13-12-27-11-10-26-9-8-25-7-6-22/h2-5,22H,6-19H2,1H3
SMILES Code: O=S(C1=CC=C(C)C=C1)(OCCOCCOCCOCCOCCOCCOCCO)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2905.31.00
More Info:
| Biological target: | Tos-PEG7-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
The following data is based on the product molecular weight 480.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1: Brown A, Patel S, Ward C, Lorenz A, Ortiz M, DuRoss A, Wieghardt F, Esch A, Otten EG, Heiser LM, Korolchuk VI, Sun C, Sarkar S, Sahay G. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder. Sci Rep. 2016 Aug 30;6:31750. doi: 10.1038/srep31750. PubMed PMID: 27572704; PubMed Central PMCID: PMC5004151.
2: Saifer MG, Williams LD, Sobczyk MA, Michaels SJ, Sherman MR. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol Immunol. 2014 Feb;57(2):236-46. doi: 10.1016/j.molimm.2013.07.014. Epub 2013 Nov 5. PubMed PMID: 24200843.
3: Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012 Nov;9(11):1319-23. doi: 10.1517/17425247.2012.720969. Epub 2012 Aug 30. PubMed PMID: 22931049.
